好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Analysis of the Epidemiologic Profile, Prevalence, and Incidence of Migraine out of 15,490 Spontaneous Intracranial Hypotension Patients from a Multicenter Record Database (TriNetX)
Headache
P2 - Poster Session 2 (11:45 AM-12:45 PM)
12-008

To investigate the incidence of migraine following spontaneous intracranial hypotension (SIH) diagnosis in patients with additional risk factors.

Treatment-refractory headaches in SIH patients may be due to new-onset migraine rather than ongoing cerebrospinal fluid (CSF) leak. Risk factors, including Ehlers-Danlos Syndrome (EDS), Postural Orthostatic Tachycardia Syndrome (POTS), lumbar puncture (LP), and motor vehicle collisions (MVC), may contribute to the refractoriness.

Using TriNetX, a cohort with ≥2 instances of either SIH, spinal CSF leak, or intracranial hypotension (excluding cranial and iatrogenic CSF leak) was created (n=15,490) and subgrouped by the following risk factors: EDS (n=507), POTS (n=301), past MVC (n=1,664), and prior lumbar puncture (LP) (n=206). In addition to the demographics, we evaluated the risk of newly diagnosed (1-year post-SIH diagnosis) migraine based on each risk factor.
In this SIH cohort, 15,490 patients were identified (prevalence 0.012%). The mean age was 53.6±19.7, 8,416 (54.3%) were female, 10,379 (67.0%) were white, 3,534 (22.8%) had migraine, and 2,317 (15.0%) were prescribed antimigraine agents. The risks of a new migraine diagnosis by risk factors were: SIH alone (3.82%), EDS (14.9%), POTS (15.0%), prior MVC (2.07%), and prior LP (6.85%).

We describe the demographics of an SIH cohort and its 1-year incidence of migraine after SIH diagnosis. SIH with comorbid EDS or POTS has a higher risk of new migraine diagnosis than SIH alone, prior MVC, and prior LP. This study is limited by reporting bias and the inability to confirm diagnoses or verify in what setting diagnoses are made.
Authors/Disclosures
Arashleen K. Pannu
PRESENTER 		Ms. Pannu has nothing to disclose.
Victor Wang, MD (Thomas Jefferson University Hospital) Dr. Wang has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Pfizer. Dr. Wang has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Abbvie.
Simy K. Parikh, MD Dr. Parikh has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Pfizer. Dr. Parikh has received personal compensation in the range of $0-$499 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Current Pain and Headache Reports. Dr. Parikh has received personal compensation in the range of $500-$4,999 for serving as a Author with Medlink. Dr. Parikh has received personal compensation in the range of $500-$4,999 for serving as a Faculty with Touch Independent Medical 好色先生 (touchIME) . Dr. Parikh has a non-compensated relationship as a Medical Advisory Board Member with Spinal CSF Leak Foundation that is relevant to AAN interests or activities.
Mario F. Peres, MD (Sao Paulo Headache Center) Dr. Peres has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eurofarma. Dr. Peres has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Eli Lilly. Dr. Peres has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Libbs. Dr. Peres has received research support from CNPq. Dr. Peres has received research support from Allergan.
Hsiangkuo Yuan, MD, PhD (Jefferson Headache Center) An immediate family member of Dr. Yuan has received personal compensation for serving as an employee of Merck. Dr. Yuan has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Pfizer. Dr. Yuan has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Abbvie. Dr. Yuan has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Pfizer. Dr. Yuan has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Salvia. Dr. Yuan has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Cerenovous. Dr. Yuan has received personal compensation in the range of $0-$499 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Regional Anesthesia and Pain Medicine. Dr. Yuan has received personal compensation in the range of $0-$499 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Current Headache and Pain Reports. Dr. Yuan has received personal compensation in the range of $0-$499 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for MedLink Neurology. Dr. Yuan has received personal compensation in the range of $0-$499 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Cephalalgia. The institution of Dr. Yuan has received research support from NIH. The institution of Dr. Yuan has received research support from American Headache Society. The institution of Dr. Yuan has received research support from Pfizer. Dr. Yuan has received publishing royalties from a publication relating to health care. Dr. Yuan has received publishing royalties from a publication relating to health care. Dr. Yuan has received personal compensation in the range of $500-$4,999 for serving as a Grant reviewer with NIH. Dr. Yuan has received personal compensation in the range of $10,000-$49,999 for serving as a Invited speaker with Chinese Stroke Association.